Allergan Acquires LiRIS® Program from TARIS Biomedical®
20 October, 2014
Allergan Inc. and Taris Holdings LCC have announced that Allergan has closed a transaction to acquire the worldwide rights to TARIS Biomedical’s® LiRIS® which is currently in Phase 2 trials for the treatment of interstitial cystitis/painful bladder syndrome.
David E I Pyott, Chairman of the Board and Chief Executive Officer, Allergan described the transaction as a ‘win win’ for patients, shareholders and employees. He stated that the acquisition of LiRIS® will prove an important addition to Allegan’s growing urology pipeline and if approved, will provide a local treatment for IC/PBS.
Allergan is prepping for phase-three clinical trials for LiRIS®, which can deliver 400 milligrams of lidocaine to patients. (Because the device stays in the bladder so long, it also allows for smaller doses, reducing adverse reactions.)
Earlier studies on the device threw up some surprising results. TARIS tested the device on IC/PBS patients with Hunner’s lesions. The lesions are usually treated by cauterization under anaesthesia but the resulting scarring can sometimes lead to patients losing some bladder function.
After treatment with the LiRIS® device the lesions disappeared after two weeks in five out of six patients. Additionally, follow up meetings suggested reduced pain several months after the device was removed.
We, at COB, are very excited about this device and will be following its development closely.